MDG1 — Medigene AG Share Price
0.000.00%
Last trade - 00:00- €33.45m
- €11.85m
- €6.03m
- 17
- 88
- 26
- 36
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.7 | ||
| Price to Tang. Book | 3.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.26 | ||
| EV to EBITDA | 1.95 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 29.71% | ||
| Return on Equity | 17.33% | ||
| Operating Margin | 25.72% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 10.63 | 8.75 | 10.99 | 31.25 | 6.03 | 10.6 | 6.95 | -4.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
Directors
- Gerd Zettlmeissl CSU (63)
- Dolores Schendel CMG
- Antoinette Hiebeler-Hasner VSU (60)
- Axelsven Malkomes CFO
- Rene Goedkoop OTH
- Anthony Man SUB
- Keith Manchester SUB (50)
- Frank Mathias SUB
- Ronald Scott SUB (63)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2023
- Incorporated
- March 4th, 1997
- Public Since
- June 30th, 2000
- No. of Employees
- 86
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- XETRA
- Shares in Issue
- 29,475,189
- Address
- Lochhamer Strasse 11, PLANEGG, 82152
- Web
- https://www.medigene.de/
- Phone
- +49 892000330
- Contact
- Pamela Keck
- Auditors
- PricewaterhouseCoopers GmbH
Upcoming Events for MDG1
Q3 2024 Medigene AG Earnings Release
Similar to MDG1
FAQ
What is the Medigene AG share price?
As of Today at 22:01 UTC, shares in Medigene AG are trading at €1.22. This share price information is delayed by 15 minutes.
How has the Medigene AG share price performed this year?
Shares in Medigene AG last closed at €1.22 and the price had moved by -38.48% over the past 365 days. In terms of relative price strength the Medigene AG share price has underperformed the FTSE Global All Cap Index by -45.9% over the past year.
What are the analyst and broker recommendations for Medigene AG?
The overall consensus recommendation for Medigene AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Medigene AG dividend yield?
Medigene AG does not currently pay a dividend.
Does Medigene AG pay a dividend?
Medigene AG does not currently pay a dividend.
When does Medigene AG next pay dividends?
Medigene AG does not currently pay a dividend.
How do I buy Medigene AG shares?
To buy shares in Medigene AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medigene AG?
As of the previous close price of €1.22, shares in Medigene AG had a market capitalisation of €35.81m.
Where are Medigene AG shares listed?
Here are the trading details for Medigene AG:
- Country of listing: Germany
- Exchange: GER
- Ticker Symbol: MDG1
What kind of share is Medigene AG?
Based on an overall assessment of its quality, value and momentum Medigene AG is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medigene AG share price forecast for 2024?
The analyst consensus target price for shares in Medigene AG is €2.60. That is 113.99% above the last closing price of €1.22.
Analysts covering Medigene AG currently have a consensus Earnings Per Share (EPS) forecast of -€0.42 for the next financial year.
What is the trend in the Medigene AG share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medigene AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -21.29%.
As of the last closing price of €1.22, shares in Medigene AG were trading -23.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medigene AG PE Ratio?
The Medigene AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €1.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medigene AG?
Medigene AG's management team is headed by:
- Gerd Zettlmeissl - CSU
- Dolores Schendel - CMG
- Antoinette Hiebeler-Hasner - VSU
- Axelsven Malkomes - CFO
- Rene Goedkoop - OTH
- Anthony Man - SUB
- Keith Manchester - SUB
- Frank Mathias - SUB
- Ronald Scott - SUB